HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The clinical significance of secreted protein acidic and rich in cysteine expression in breast cancer tissue and its association with prognosis.

AbstractOBJECTIVE:
The aim of this study was to evaluate the secreted protein acidic and rich in cysteine (SPARC) expression in breast cancer tissue and its association with patients' clinical pathology characteristics and prognosis.
MATERIALS AND METHODS:
Eight-eight cases with confirmed diagnosis of breast cancer who received operation from January 2010 to February 2016 were included in this study. The SPARC expression in cancer tissue was examined by immunohistochemical method. The SPARC expression status, clinical pathology characteristics, and prognosis of included patients were recorded and evaluated.
RESULTS:
SPARC protein was mainly expressed in cytoplasm and stroma of tumor tissue with dark brown and purple stain. The SPARC protein-positive expression rate was 69.3% (61/88) in cancer tissue. The positive expression of SPARC in breast tissues was not significantly correlated with age, menstruation status, tumor, node, and metastasis stage, tumor size, progesterone level, and HER-2 status (P > 0.05). However, SPARC protein-positive expression was correlated with tumor differentiation (P < 0.05), estrogen receptor expression (P < 0.05), and lymph node metastasis (P < 0.05). The 3-year disease-free survival (DFS) was 60.8% and 71.2% for SPARC-positive and -negative groups with no statistical difference (P > 0.05); there was no statistical difference of disease progression risk between the SPARC-positive and -negative groups (hazard ratio = 1.78, 95% confidence interval: 0.80-3.57, P > 0.05). However, SPARC-positive and -negative patients have shown a trend of DFS difference.
CONCLUSION:
SPARC is closely related to the development of breast cancer and can be used as a tumor marker for breast cancer recurrence.
AuthorsWei Guo, Mingliang Zhang, Yong Chen, Suyang Guo
JournalJournal of cancer research and therapeutics (J Cancer Res Ther) Vol. 13 Issue 5 Pg. 833-836 ( 2017) ISSN: 1998-4138 [Electronic] India
PMID29237913 (Publication Type: Journal Article)
Chemical References
  • Biomarkers, Tumor
  • Osteonectin
  • SPARC protein, human
  • ERBB2 protein, human
  • Receptor, ErbB-2
Topics
  • Adult
  • Aged
  • Biomarkers, Tumor (metabolism)
  • Breast (pathology)
  • Breast Neoplasms (mortality, pathology)
  • Disease Progression
  • Disease-Free Survival
  • Feasibility Studies
  • Female
  • Humans
  • Incidence
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Recurrence, Local (epidemiology, pathology)
  • Osteonectin (metabolism)
  • Prognosis
  • Receptor, ErbB-2 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: